You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


MHRA extends Cosentyx licence for paediatric arthritis

Novartis has announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Cosentyx – also known as secukinumab.